A phase II trial using the FASN inhibitor TVB‐2640 (also known as ASC40) in combination with the anti‐angiogenic antibody bevacizumab in recurrent GBM has shown optimistic results recently (NCT03032484). This evidence concerns the gene FASN and glioblastoma.